Advantest is overvalued at the moment, but worth understanding its recent 24 months astonishing rise 🚀 
Advantest and U.S.-based rival Teradyne hold a combined 80% global market share.
They long stood neck and neck, but the Japanese player gained the upper hand around 2022, when generative AI began to attract attention.
Advantest widened its share to about 50% in 2023 compared with Teradyne’s roughly 30%.
Shares are trading at more than 70 times forward earnings. But based on the market forecast of earnings per share for the year ending March 2026, shares look less pricy, at around 40 times.

6857